The Relationship Between the Therapeutic Alliance and Treatment Outcome in Two Distinct Psychotherapies for Chronic Depression

Bruce A. Arnow, Dana Steidtmann, Christine Blasey, and Rachel Manber  
Stanford University School of Medicine  

Michael J. Constantino  
University of Massachusetts Amherst  

Daniel N. Klein  
State University of New York at Stony Brook  

John C. Markowitz  
Columbia University/New York State Psychiatric Institute  

Barbara O. Rothbaum  
Emory University School of Medicine  

Michael E. Thase  
University of Pennsylvania School of Medicine  

Aaron J. Fisher  
Stanford University School of Medicine  

James H. Kocsis  
Weill Medical College of Cornell University  

Objective: This study tested whether the quality of the patient-rated working alliance, measured early in treatment, predicted subsequent symptom reduction in chronically depressed patients. Secondarily, the study assessed whether the relationship between early alliance and response to treatment differed between patients receiving cognitive behavioral analysis system of psychotherapy (CBASP) vs. brief supportive psychotherapy (BSP). Method: 395 adults (57% female; M_age = 46; 91% Caucasian) who met criteria for chronic depression and did not fully remit during a 12-week algorithm-based, open-label pharmacotherapy trial were randomized to receive either 16–20 sessions of CBASP or BSP in addition to continued, algorithm-based antidepressant medication. Of these, 224 patients completed the Working Alliance Inventory-Short Form at Weeks 2 or 4 of treatment. Blind raters assessed depressive symptoms at 2-week intervals across treatment using the Hamilton Rating Scale for Depression. Linear mixed models tested the association between early alliance and subsequent symptom ratings while accounting for early symptom change. Results: A more positive early working alliance was associated with lower subsequent symptom ratings in both the CBASP and BSP, \( F(1, 1236) = 62.48, p < .001 \). In addition, the interaction between alliance and psychotherapy type was significant, such that alliance quality was more strongly associated with symptom ratings among those in the CBASP treatment group, \( F(1, 1234) = 8.31, p = .004 \). Conclusions: The results support the role of the therapeutic alliance as a predictor of outcome across dissimilar treatments for chronic depression. Contrary to expectations, the therapeutic alliance was more strongly related to outcome in CBASP, the more directive of the 2 therapies.

Keywords: alliance, depression, psychotherapy outcome, REVAMP

Considerable evidence associates the therapeutic alliance with psychotherapy outcome for a wide range of diagnoses and populations (Castonguay, Constantino, & Holtforth, 2006). A recent meta-analysis of 190 independent alliance–outcome association studies (Horvath, Del Re, Flückinger, & Symonds, 2011) reported a modest but significant relationship between alliance quality and outcome (weighted \( r = .28, p < .0001, CI_{95} [.25, .30] \)). Nonetheless, methodological problems in the extant literature on the
influences one’s perception of the alliance, or because the two variables mutually influence one another (Barber, Connolly, Crits-Christoph, Gladis, & Siqueland, 2000). As Feeley, DeRubeis, and Gelfand (1999) noted, existing studies on the alliance–outcome relationship have generally been observational rather than experimental. Observational studies allow inference of causal implications only if certain conditions are met, a crucial one being temporal precedence between the process (e.g., alliance) and outcome (e.g., symptom severity) variables (DeRubeis & Feeley, 1990; Feeley et al., 1999). To support the hypothesis that a good therapeutic alliance mediates therapy outcome, the alliance must be shown to predict outcome at a subsequent time point, while accounting for change on the outcome variable prior to alliance measurement (Kraemer, Wilson, Fairburn, & Agras, 2002).

Few studies meet these criteria (Barber, 2009). Reports on the relationship between the alliance and outcome have been limited by (a) Correlating the alliance assessed at time point A with subsequent outcome at posttreatment without accounting for the possibility that some of the predicted change had already occurred prior to time point A and (b) correlating improvement in the outcome variable from pre- to posttreatment with an average of alliance scores across the course of treatment (Barber, Khalsa, & Sharpless, 2010; Feeley et al., 1999; Klein et al., 2003; Kraemer et al., 2002).

Among the relatively small number of studies that have investigated the temporal nature of the association between alliance and outcome in patients with depression, results are inconsistent. We are aware of three studies in which researchers have examined whether alliance predicts subsequent outcome without controlling for change in symptoms prior to the alliance assessment; none of these demonstrated a significant alliance–outcome link. DeRubeis and Feeley (1990) reported that alliance at Treatment Week 2 did not predict subsequent residual change in depression severity in a small sample of 25 patients diagnosed with major depressive disorder (MDD) who received cognitive therapy (CT). Interestingly, researchers of this study found the converse, that prior change in depressive symptoms predicted quality of the alliance measured during Treatment Weeks 7–9 and 10–12. In another small study of 25 patients with MDD receiving CT, Feeley et al. (1999) again found that Week 2 alliance did not predict subsequent symptom change; this report did not replicate the earlier converse finding that symptom change predicted later alliance (DeRubeis & Feeley, 1990). A study of 60 patients with MDD treated with CT examined the association between repeated measures of the alliance and session-to-session symptom improvement across the first five sessions of treatment (Strunk, Brotman, & DeRubeis, 2010). The alliance did not predict intersession reductions in symptoms, but prior symptom change did predict subsequent alliance strength (Strunk et al., 2010). These investigators did not examine outcome beyond 5 weeks.

Four studies conducted with depressed patients examined whether alliance predicts subsequent outcome, while also controlling for change in outcome prior to measuring the alliance. This reflects the most stringent test of the temporal associations between alliance and symptom change. In a study of 54 elderly patients with MDD who received either brief dynamic therapy, behavior therapy, or CT, Gaston, Marmar, Gallagher, and Thompson (1991) reported that the relationship between alliance and outcome across all three treatments was not significant. Three other studies found that alliance quality predicted subsequent change in symptoms when accounting for symptom change prior to alliance assessment. In a study involving 367 chronically depressed patients treated with either cognitive behavioral analysis system of psychotherapy (CBASP) or CBASP plus medication, the alliance significantly predicted subsequent change in depressive symptoms while controlling for prior symptom change and other patient characteristics with the potential to influence the alliance (Klein et al., 2003); neither early level of symptoms nor early change in symptoms predicted the subsequent level or course of the alliance. In a study of 45 patients with MDD treated with an alliance-enhancing therapy (Crits-Christoph et al., 2006), after controlling for early change in symptoms, early alliance predicted change in depression scores from baseline to end of treatment (Crits-Christoph, Gibbons, Hamilton, Ring-Kurtz, & Gallop, 2011). These investigators also measured alliance later in treatment and found that an average of alliance assessments conducted at Sessions 3–9 had an even stronger relationship with outcome than the early alliance (Crits-Christoph et al., 2011), though this association did not control for previous symptom change. Finally, Webb and colleagues (2011) examined the alliance in 105 depressed patients treated with CT in two separate randomized controlled trials. An observer-rated version of early alliance was used and was found to significantly predict outcome.

The inconsistent findings of studies that have reported on the relationship between alliance and subsequent symptom change (with or without control for early symptom change) may be related to (a) the model of psychotherapy used and (b) failure to examine specific dimensions of the alliance. Although the data are mixed (Hatcher & Gillaspy, 2006), theory suggests that the alliance is composed of different components, specifically tasks, goals, and the therapist–patient emotional bond (Bordin, 1979). Different psychotherapy models may evoke different alliance types, expressed through different scoring patterns on alliance dimensions (Hatcher & Gillaspy, 2006). Webb et al. (2011) reported that symptom change in patients who received CT was related to an alliance factor assessing agreement on goals and tasks, but not to the therapist–patient bond factor.

All but one of the previously cited studies involved only a single treatment, precluding comparison of alliance effects across treatments. In the one study that involved more than one psychotherapy model, the sample size was too small to adequately examine potential differences (Gaston et al., 1991). Thus, no studies examining the alliance–outcome relationship in depressed patients have reported on between-treatment differences in dimensions of the alliance.

In the current study, we examined the relationship between early alliance and subsequent change in depressive symptoms in two distinct psychotherapies, namely CBASP or brief supportive psychotherapy (BSP), while accounting for prior symptom change in a single-patient population, consisting of chronically depressed patients. Chronically depressed patients may present unique difficulties in developing and maintaining productive therapeutic alli-


rances. McCullough (2000) has argued that the chronically depressed patient is distinguished by preoperational thinking (Piaget, 1926, 1967) involving features such as egocentric views of the self and others, impaired empathy, and lack of responsiveness to corrective feedback. Although interpersonal difficulties such as social skills deficits and interpersonal dependency are characteristic of depressed patients in general (Joiner & Timmons, 2009), the chronically depressed patient, according to McCullough, is unique in his or her failure to understand the relationship between thinking, behavior, and environmental consequences. In turn, this results in a lack of effective agency, and a wariness of interpersonal engagement (Constantino et al., 2008). The interpersonal style of the chronically depressed patient, according to McCullough, manifests as either hostile detachment or excessive submissiveness. In a test of McCullough’s theory, based on data gathered in several samples using the Impact Message Inventory (Kiesler & Schmidt, 1993), Constantino et al. (2008) found that chronically depressed patients, compared with an acutely depressed sample, had significantly greater hostile and lower friendly-dominant impacts on their therapists. Compared with a normative comparison group, chronically depressed patient impacts were significantly more hostile and hostile-submissive, and significantly less friendly dominant.

Our primary hypothesis was that a stronger early therapeutic alliance would predict a significantly greater treatment response both for patients receiving CBASP and for patients receiving BSP. For CBASP, this hypothesis stemmed from previous findings reported by Klein et al. (2003). For BSP, the expectation of an alliance–outcome association is consistent with the model’s putative focus on “common factors,” including the therapeutic alliance (Markowitz, Manber, & Rosen, 2008). As Markowitz et al. (2008) noted, although all psychotherapies use common factors, “they . . . do so to differing degrees” (p. 71). Given BSP’s emphasis on the therapeutic alliance and its de-emphasis of the procedural interventions characteristic of CBASP and other structured psychotherapy models, we further hypothesized that the magnitude of the alliance–outcome correlation would be greater in BSP than CBASP. Additional aims were to explore whether CBASP and BSP differed in alliance development and, if so, whether the two models were associated with differences in the dimensions of early alliance. On the basis of the findings of Strunk et al. (2010) and DeRubeis and Feeley (1990), we also aimed to evaluate the complementary hypothesis that early symptom reduction would predict therapeutic alliance rating across treatment.

Method

The current study reports data from Phase 2 of the Research Evaluating the Value of Augmenting Medication With Psychotherapy (REVAMP) trial. The REVAMP trial design has been described in detail elsewhere (Kocsis et al., 2009). Briefly, it comprised two phases. In the nonrandomized Phase 1, all participants received algorithm-driven antidepressant medication. Those who did not achieve remission (defined as at least a 60% reduction in Hamilton Rating Scale for Depression score [HAM-D]; Hamilton, 1960), a 24-item total HAM-D score of 7 or less, and not meeting Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM–IV–TR) criteria for MDD over two consecutive visits during Weeks 6 through 12 continued to Phase 2, in which they were randomly assigned to receive CBASP + antidepressant medication (ADM), BSP + ADM, or ADM only. Phase 2 findings revealed no differences between the three conditions in remission, partial response, or change in HAM-D scores. Among all participants, remission was achieved in 15%, and partial response in 22.5% (Kocsis et al., 2009). Secondary mixed model analyses revealed significantly lower mean HAM-D scores in the CBASP versus BSP comparison (p = .04), although the two groups did not differ in rate of change.

Participants

Participants were outpatients, age 18–75, recruited at eight separate sites. Institutional Review Board committees at each site approved the study. All patients met DSM–IV–TR criteria (American Psychiatric Association, 2000) for current MDD as determined by the Structured Clinical Interview for DSM–IV Axis I Disorders, Patient Edition (SCID-P; First, Spitzer, Gibbon, & Williams, 1996). All patients had experienced the current MDD episode for a minimum of 4 weeks, and all had experienced depressive symptoms for at least 2 years without remission, thus meeting criteria for chronic MDD, recurrent MDD with incomplete interepisode recovery, or “double depression” (current MDD episode with antecedent dysthymic disorder). In addition, participants scored at least 20 on the 24-item HAM-D (Hamilton, 1960) at baseline and spoke English.

Exclusion criteria were current diagnosis of any psychotic disorder; dementia; or antisocial, schizotypal, or severe borderline personality disorder; current primary diagnosis of posttraumatic stress disorder, anorexia, bulimia, or obsessive-compulsive disorder; history of bipolar disorder; previous CBASP treatment; previous nonresponse to four or more steps of pharmacotherapy algorithm; unwillingness to terminate other psychiatric treatment during the study; pregnancy; serious unstable medical illness; and current alcohol or substance dependence (except nicotine dependence) that required detoxification. Participants with alcohol and substance abuse were not excluded if they agreed to participate in Alcoholics Anonymous or chemical dependence counseling and to implement a sobriety plan while participating in the study.

Pharmacotherapy

All patients received concomitant algorithm-based pharmacotherapy. The pharmacotherapy algorithm (Klein et al., 2009; Kocsis et al., 2009) was based on other empirically derived regimens including the Sequenced Treatment Alternatives to Relieve Depression study (Fava et al., 2003). The study medications included sertraline, escitalopram, bupropion XL, venlafaxine XR, mirtazapine, and lithium. Prior treatment history determined choice of initial medication; treatment naïve patients began on sertraline. Minimum and maximum doses, speed of dosage escalation, and trial lengths after each change were specified by the protocol.

Participants were evaluated every 2 weeks. Participants who were intolerant to a medication during the first 4 weeks of Phase 1 could move to the next option in the sequence. Pharmacotherapists followed the Fawcett, Epstein, Fiester, Elkin, and Autry (1987) manual from the National Institute of Mental Health Treat-
ment of Depression Collaborative Research Program (NIMH TDCRP; Elkin et al., 1989) to ensure minimal psychotherapeutic intervention.

CBASP

CBASP is a manualized, time-limited, cognitive-behavioral intervention designed specifically for patients suffering from chronic depression (McCullough, 2000). A primary assumption of CBASP is that chronically depressed patients fail to understand the relationships among their own thoughts, behaviors, and environmental consequences. Situational analysis, a core CBASP procedure, is a social problem-solving algorithm designed to modify maladaptive thoughts and behaviors and enhance awareness of the consequences of one’s own thoughts and behaviors (Arnow, 2005; McCullough, 2000). Patients are asked to track distressing interpersonal situations between sessions using the Coping Style Questionnaire (McCullough, 2000). During situational analysis, the patient and therapist examine the associations among thoughts, behaviors, and actual and desired outcomes in specific interpersonal encounters. CBASP focuses on examining discrepancies between actual and desired outcomes and on how thinking and behavior need to change in order to increase the likelihood of achieving the desired outcome. If the desired outcome is unrealistic, the therapist works with the patient to formulate a more achievable goal. CBASP therapists formulate transference hypotheses at the beginning of treatment and implement explicit procedures for addressing interactions within the therapeutic relationship that are inconsistent with the patient’s relationship expectations (McCullough, 2000), with the goal of teaching the patient the situational specificity of others’ reactions to their behavior.

CBASP emphasizes the importance of “disciplined personal involvement” (McCullough, 2000) on the part of the psychotherapist in promoting a sound therapeutic alliance. This requires the therapist’s willingness to productively make use of both positive and negative reactions to the patient. Positive reactions were often contrasted with the responses of significant others in the patient’s history. For instance, a therapist’s willingness to accept a patient’s angry response might be contrasted with the habitual response of significant others in the patient’s history (e.g., “What are the implications both for our relationship and for your relationship with others of my willingness to accept and take seriously your anger toward me?”). When the therapist has negative responses toward a patient, procedures included verbalizing the response, identifying the specific behavioral precipitant and its impact on the therapist, and using the interaction to improve the patient’s understanding of his or her interpersonal impact on the therapist and on others.

CBASP sessions occurred twice weekly during Weeks 1–4 and once weekly during Weeks 5–12. During Weeks 5–8, up to four additional sessions could be added if a participant needed additional assistance in mastering situational analysis. Thus, total CBASP treatment ranged from 16 to 20 sessions.

BSP

BSP resembled client-centered (Rogers, 1951) therapy with added psychoeducation regarding chronic depression. It was designed to control for the nonspecific elements of psychotherapeutic treatment and to provide a contrast with the more structured CBASP (Markowitz, Manber, & Rosen, 2008). The model used in the REVAMP study was similar to that used in studies of depressed HIV-positive (Markowitz et al., 1998) dysthymic (Markowitz, Kocsis, Bleiberg, Christos, & Sacks, 2005) and chronically depressed alcohol abuse patients (Markowitz, Kocsis, Christos, Bleiberg, & Carlin, 2008). Therapists conducting BSP used an unpublished treatment manual that drew on the principles of supportive psychotherapy (Novalis, Rojcewicz, & Pellec, 1993; Pinker, 1997) and emphasized the following “common” psychotherapeutic factors (Frank, 1963; Rogers, 1951): reflective listening, empathic therapeutic responses, evoking affect, normalizing patient feelings such as anger and sadness, imparting therapeutic hope, encouraging patients to find solutions rather than directly suggesting them, and highlighting success experiences (Markowitz, Manber, & Rosen, 2008). Patients determined the session focus and pace, making sessions much less structured than in CBASP. Therapists elicited patients’ emotional reactions and highlighted patients’ strengths. Specific interpersonal, cognitive, behavioral, and psychodynamic interventions were prohibited (Markowitz, Manber, & Rosen, 2008). As in CBASP, 16–20 sessions of BSP were scheduled over 12 weeks.

Forming an understanding and supportive therapeutic alliance is a primary goal of BSP. Therapists sought to achieve this by letting patients determine subject matter, listening carefully, mirroring patient affects in their own emotional responses during a session (e.g., looking sad when a patient described a sad situation or feeling), echoing their feelings (“It really hurts, doesn’t it?”), using therapeutic silence to allow feelings to build in the room to demonstrate that therapists could tolerate “noxious” patient feelings, and providing support and encouragement. In short, the alliance was fostered by helping the patient to feel that the therapist understood and empathized with him or her (Frank, 1963).

Psychotherapists

All psychotherapists were licensed and had at least 2 years of clinical experience after completing a doctorate degree in psychology or a psychiatric residency, or at least 5 years of experience after completing a master’s in social work degree. BSP therapists were comparable to CBASP therapists in type of professional degree and amount of clinical experience.

Supervision and Protocol Adherence

The developer of CBASP, James P. McCullough, Jr., PhD, trained and certified CBASP therapists and site supervisors. Similarly, John C. Markowitz, MD, trained and certified BSP therapists and site supervisors. All psychotherapy sessions were videotaped. Supervision was conducted by site supervisors who met weekly with therapists. Drs. McCullough and Markowitz provided monthly phone supervision to the full group of site CBASP and BSP supervisors, respectively.

For both psychotherapy conditions, one or two session tapes for each therapist–patient dyad were randomly selected and rated for protocol adherence. Tapes were taken from early (Session 2–6) and/or late (Session 8 or later) sessions and rated in their entirety using the Collaborative Study Psychotherapy Rating Scale from
the NIMH TDCRP (Elkin et al., 1989), modified to also rule out situational analysis (for BSP), and the CBASP Therapist Adherence Rating Scale (for CBASP).

Randomization

Randomization in Phase 2 was stratified by site, Phase 1 response status (nonresponse vs. partial response), and medication history (failure to respond to fewer than three adequate medication trials including Phase 1 trials, vs. failure to respond to three or more adequate trials). The randomization allocation ratio was 2:2:1 (CBASP + ADM:BSP + ADM:ADM only). Only the CBASP + ADM and BSP + ADM treatment groups are included in the current study.

Measures and Procedure

Depressive symptoms. Raters assessed participant depressive symptoms every 2 weeks using the 24-item HAM-D (Hamilton, 1960). The 24-item version was selected because it contains cognitively significant items characteristic of chronically depressed individuals. Raters were blind to treatment condition. Rater and therapist offices were physically separated at each site, and raters began each assessment by requesting that participants not refer to psychotherapists during the interview.

Global Assessment of Functioning. Trained raters assessed level of impairment due to psychiatric symptoms at baseline using the Global Assessment of Functioning Scale (GAF; Endicott, Spitzer, Fleiss, & Cohen, 1976). The GAF is a single numerical rating designed to capture an individual’s psychological, social, and occupational functioning. Scores range from 1 to 100, divided into 10-point intervals, each with a set of distinguishing characteristics. The GAF has demonstrated good interrater reliability (ICC > .86) and correlated moderately with other general symptom severity measures in a sample seeking outpatient mental health treatment (Hilsenroth et al., 2000).

Therapeutic alliance. Because the current study focused on the therapeutic alliance in psychotherapy, alliance data were not collected in the medication-only group. For the CBASP and BSP conditions, the patient-rated short form of the Working Alliance Inventory (WAI; Horvath & Greenberg, 1989; Tracey & Kokotovic, 1989) was administered at three time points across Phase 2: early (Week 2 or Week 4), middle (Week 6), and late (Week 12). Due to an administrative error, the WAI was not given at Week 2–41 of 224 (18%) participants in this study. In these instances, the Week 4 score served as the early alliance score. Patients providing alliance data at Week 2 did not statistically differ from those providing data at Week 4 on any baseline or outcome measure (e.g., GAF, early symptom change, overall symptom reduction).

The WAI short form is a 12-item self-report measure derived from the full 36-item WAI (Tracey & Kokotovic, 1989). It has been widely used to assess therapeutic alliance. The full WAI correlates moderately with other alliance measures (Horvath & Greenberg, 1989), and scores on both the full form (Horvath, 1994) and short form (Klein et al., 2003) have predicted psychotherapy outcome. We used the patient form because it predicts psychotherapy outcome more strongly than psychotherapist-rated assessment of the alliance (Barber et al., 1999; Constantino, Cas tonguay, & Schut, 2002; Horvath & Symonds, 1991). Because participants had two treating clinicians, a pharmacotherapist and a psychotherapist, the instructions clarified that the measure should be completed specifically regarding their psychotherapists.

Items are rated on a 7-point Likert scale with higher scores reflecting a stronger therapeutic alliance. Both the original and the shortened versions of the WAI have a purported two-level structure, with a general alliance factor that can be divided into three subscale scores: (a) Goals, designed to measure therapist and patient agreement on the goals for therapy; (b) Tasks, designed to measure therapist and patient agreement on how to achieve treatment goals; and (c) Bond, designed to measure the quality of the therapist–patient relationship (Tracey & Kokotovic, 1989).

Statistical Analyses

Descriptive data were calculated for the total sample and by treatment group. Between-subjects descriptive variables were compared using independent samples t tests for continuous data and chi-square analyses for categorical data. Within-subjects descriptive variables were compared using paired samples t tests. Internal consistency of the WAI was examined by calculating Cronbach’s alpha for the early, middle, and late WAI total scores.

A linear mixed model was used to test the main study hypothesis that stronger early alliance would predict greater treatment response. Fixed factors in the model included early WAI total score, treatment group, the interaction of WAI total score with treatment group, patient age, patient gender, baseline functioning (GAF), and early change in HAM-D (i.e., Week 2 score minus baseline HAM-D score). For the 46 patients whose early alliance was assessed at Week 4, the early change in symptoms variable was calculated using Week 4 minus baseline HAM-D score. Early change in HAM-D was included on the basis of the assumption that early response to treatment could influence both early treatment alliance and treatment outcome. Baseline GAF was included on the assumption that initial severity may correlate with response to treatment. GAF was chosen rather than baseline HAM-D because of potential multicollinearity with the change in early symp toms variable and because it incorporates a greater range of prognostically relevant information (e.g., comorbid symptomatology, functional impairment). Continuous predictor variables were mean centered, and dichotomous variables were coded as 0 or 1. The dependent variable was HAM-D total score measured at Weeks 2, 4, 6, 8, and 12 of treatment (or Weeks 4, 6, 8, and 12 for those participants completing the WAI at Week 4). HAM-D observations were specified as a repeated measures variable based on time.

A similar linear mixed model was used to test whether early HAM-D symptom reduction predicted subsequent alliance. This model also tested whether CBASP + ADM and BSP + ADM treatment groups differed in development of the alliance. Centered values for early symptom change, treatment group, the interaction of early symptom change with treatment group, GAF and patient age, and dichotomous values for patient gender were entered as fixed factors. The dependent variable was WAI total score at Weeks 2 (or 4), 6, and 12. Mixed model analyses were conducted using the MIXED procedure in SPSS. An alpha of .05 was used for defining statistical significance in all analyses.

Effect size is reported as Cohen’s d. The Cohen’s d statistic can be calculated from any statistical analysis that yields a t statistic
via the equation \( d = t(2n)^{1/2} \) (Dunlap, Cortina, Vaslow, & Burke, 1996). Additionally, for comparison with studies reporting effects as \( r \) values, the \( t \) statistic can be used to generate \( r \) via the equation \( r = [t^2/(t^2 + df)]^{1/2} \).

Results

Descriptive Characteristics

Sample demographics appear in Table 1. There were no statistically significant differences between the two treatment groups on baseline variables. Two hundred participants were randomized to CBASP + ADM, and 195 were randomized to BSP + ADM. Of these, data on the variables of interest were available for 111 participants in CBASP + ADM (56% of total CBASP + ADM sample) and 113 participants in BSP + ADM (58% of total BSP + ADM sample). Patients in the current study sample did not differ from participants in the larger study on any parameter (see Table 1).

Mean HAM-D scores across treatment appear in Figure 1. Consistent with findings of the main outcome study (Kocsis et al., 2009), HAM-D scores decreased in both groups during the 12-week trial (BSP + ADM: mean change from baseline = −6.7, \( SD = 7.3 \), paired \( t = 9.3, df = 103, p < .001 \); CBASP + ADM: mean change from baseline = −7.3, \( SD = 7.0 \), paired \( t = 10.7, df = 106, p < .001 \)). Mean WAI scores, measured during the early (Week 2 or 4), middle (Week 6), and late phases (Week 12) of the study appear in Figure 2. WAI scores increased significantly during the course of the study in both the BSP + ADM and CBASP + ADM groups (BSP + ADM: \( M = +5.4, SD = 9.0, t = 5.9, df = 98, p < .001 \); CBASP + ADM: \( M = +3.5, SD = 10.2, t = 3.4, df = 93, p < .001 \)). Internal consistency of the WAI was high at each time point (Cronbach’s \( \alpha = .90, .90, \) and .93 for Weeks 2, 6, and 12, respectively).

Prediction of Symptom Outcome From Early Therapeutic Working Alliance

The mixed model analysis testing the primary hypothesis showed, as predicted, that higher early working alliance scores were significantly associated with lower subsequent HAM-D scores across treatment, \( F(1, 1236) = 62.48, p < .001 \). Parameter estimates appear in Table 2. The Treatment Group × Alliance interaction was also significant; however, the direction was contrary to prediction, indicating that the association between alliance and subsequent symptom reduction was stronger among those in CBASP + ADM when compared with those in BSP + ADM, \( F(1, 1234) = 8.31, p = .004 \). Greater reduction in HAM-D scores in the initial weeks of treatment significantly predicted lower subsequent HAM-D scores, \( F(1, 1233) = 40.57, p < .001 \), as did higher baseline level of functioning as measured by the GAF, \( F(1, 1218) = 84.85, p < .001 \), and CBASP treatment group, \( F(1, 1237) = 4.19, p = .04 \), although treatment groups did not significantly differ at the study end point. Age and gender were not predictive of HAM-D symptom reduction.

In order to further assess the finding that the association between alliance and HAM-D symptom reduction was stronger in CBASP + ADM than in BSP + ADM, additional mixed models analyses were run separately for each treatment group. The models were similar to the main analysis except that treatment group and the interaction of early alliance rating with treatment group were removed as fixed factors. As in the combined model, significant predictors for both treatment groups were baseline GAF, early alliance, and early HAM-D symptom change. In addition, there was a trend for younger age to predict greater HAM-D symptom reduction in the CBASP + ADM group but not in the BSP + ADM group. The estimated effect of early working alliance on HAM-D symptom reduction at each time point is shown in Table 2. The estimated effect of early working alliance on HAM-D symptom reduction across treatment was \( -.22 \) compared with \( -.11 \) in BSP + ADM. Thus, over the course of treatment, those in CBASP + ADM showed an average HAM-D-point decrease of 1.32 for each additional point increase on the WAI, whereas those in BSP + ADM showed an average HAM-D decrease of .66 for each additional point increase on the WAI. Cohen’s \( d \) for early working alliance was 1.00 in CBASP + ADM compared with .48 in BSP + ADM.

Prediction of Therapeutic Working Alliance From Early Symptom Reduction

In the mixed model analysis evaluating whether treatment group or early symptom reduction predicted average alliance scores over treatment, early change in HAM-D did not predict mean therapeutic alliance ratings across treatment as a main effect, \( F(545) = 1.48, p = .23 \), or interact with treatment group to predict alliance, \( F(1, 545) = 0.02, p = .90 \). Treatment group was predictive of therapeutic alliance such that mean alliance ratings across treatment were higher among those in CBASP + ADM when compared with those in BSP + ADM, \( F(1, 543) = 4.10, p = .04 \). Parameter estimates indicated that, on average, those in CBASP + ADM showed mean alliance ratings that...
were an average of 1.86 points higher on the WAI than those in BSP/ADM. Older age was predictive of stronger alliance, $F(1, 544) = 10.94, p < .001$, and there was a trend for women to show higher alliance ratings than men, $F(1, 543) = 3.09, p = .08$. Baseline GAF did not predict mean alliance, $F(1, 543) = 0.85, p = .36$.

**Treatment Group Differences in Therapeutic Working Alliance Ratings**

In order to explore treatment group differences in the alliance–outcome relationship, bivariate Pearson correlations between early alliance and HAM-D total scores at all time points were computed for each treatment group. Correlations appear in Table 4. Among patients who received CBASP + ADM, early alliance accounted for 4.4%–12.3% of the total variance in depressive symptoms between Weeks 4 and 12. Among patients receiving BSP + ADM, early alliance was not significantly correlated with symptom ratings except at Week 6, where it explained 5.3% of the variance in depressive symptom on the HAM-D.

An additional exploratory analysis was conducted to identify whether particular aspects of the alliance differed between the

---

**Figure 1.** Mean HAM-D scores across the 12-week study. Error bars represent standard error of the mean. Group means did not statistically differ at baseline ($p = .44$), Week 2 ($p = .49$), Week 4 ($p = .58$), Week 6 ($p = .13$), or Week 12 ($p = .30$). Those in CBASP + ADM showed lower mean HAM-D scores than those in BSP + ADM at Week 10 ($p = .05$; $M_{[SD]}^{BSP} = 14.80 [9.44]$; $M_{[SD]}^{CBASP} = 12.41 [8.12]$). There was a trend for those in CBASP + ADM to show lower mean HAM-D scores at Week 8 ($p = .06$). BSP = brief supportive therapy; CBASP = cognitive behavioral analysis system of psychotherapy; ADM = antidepressant medication; HAM-D = Hamilton Rating Scale for Depression.

**Figure 2.** Scores across treatment on the Working Alliance Inventory. Error bars represent standard error of the mean. Early treatment $n = 113$ in BSP + ADM and 111 in CBASP + ADM; Middle treatment $n = 73$ in BSP + ADM and 63 in CBASP + ADM; Late treatment $n = 99$ in BSP + ADM and 94 in CBASP + ADM. BSP = brief supportive therapy; CBASP = cognitive behavioral analysis system of psychotherapy; ADM = antidepressant medication; WAI = Working Alliance Inventory.
groups. A one-way analysis of variance was used to compare mean early alliance subscale scores on the WAI (Tracy & Kokotovic, 1989) between those in the CBASP + ADM and BSP + ADM subgroups. There were no significant differences in the Bond subscale between the two treatment groups, F(1, 220) = 0.01, p = .94. However, compared with those in BSP + ADM, those in CBASP + ADM showed higher mean ratings on Tasks, F(1, 220) = 6.22, p < .05, M (SD)_{BSP} = 21.65 (4.54), M (SD)_{CBASP} = 23.05 (3.80), and Goals subscales of the WAI, F(1, 216) = 4.31, p < .05, M (SD)_{BSP} = 22.54 (4.04), M (SD)_{CBASP} = 23.62 (3.59).

**Discussion**

We examined the association between early psychotherapeutic alliance and subsequent symptom change across treatment in a large sample of chronically depressed patients receiving two different psychotherapy models, CBASP or BSP, combined with ADM. We also tested an alternative explanation for the relationship between the alliance and outcome, namely that early symptom change predicts subsequent alliance. Additionally, we tested whether patients in these two treatments differed in alliance development and in dimensions of the alliance early in treatment.

Consistent with the primary hypothesis, in both the CBASP + ADM and BSP + ADM conditions, early alliance significantly predicted subsequent depressive symptom ratings. Furthermore, we observed these relationships after accounting for the variance in outcome associated with baseline functioning and symptom change occurring prior to the alliance assessment. Our findings on the alliance–outcome association in CBASP replicate those of Klein et al. (2003), who found that alliance predicted subsequent depressive symptoms, controlling for change prior to alliance assessment among chronically depressed patients receiving CBASP + ADM as well among patients receiving only CBASP. We know of no findings testing the relationship between alliance and outcome in patients receiving BSP, alone or with antidepressant(s), but our findings appear consistent with the conceptualization of BSP as a “common factors” treatment (Markowitz, Manber, & Rosen, 2008) emphasizing features that are shared across different models of psychotherapy, including the therapeutic alliance.

In the combined mixed model involving the full study sample, early alliance, baseline GAF, treatment arm, early change in depressive symptoms, and the interaction of treatment arm with early alliance, and GAF continued to predict in both conditions. Although we had hypothesized that the alliance would predict outcome in both BSP and CBASP, the role of the therapeutic alliance presumably functions differently in these two models. In contrasting the alliance in CBT-oriented therapies with other models, Castonguay, Constantino, McAleavey, and Goldfried (2010) noted that CBT models rely on specific techniques that produce change “on their own” (p. 154), whereas other psychotherapy models may conceptualize the alliance as “a change mechanism

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>SE</th>
<th>t</th>
<th>Significance</th>
<th>95% CI Lower</th>
<th>95% CI Upper</th>
<th>d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>14.43</td>
<td>.45</td>
<td>34.16</td>
<td>p &lt; .001</td>
<td>14.93</td>
<td>16.71</td>
<td>4.59</td>
</tr>
<tr>
<td>Female gender</td>
<td>−.06</td>
<td>.62</td>
<td>.11</td>
<td>p = .91</td>
<td>−1.29</td>
<td>1.14</td>
<td>.01</td>
</tr>
<tr>
<td>Age</td>
<td>.01</td>
<td>.03</td>
<td>.45</td>
<td>p = .66</td>
<td>.04</td>
<td>.07</td>
<td>.06</td>
</tr>
<tr>
<td>Baseline GAF</td>
<td>−.25</td>
<td>.04</td>
<td>−6.80</td>
<td>p &lt; .001</td>
<td>−.32</td>
<td>−.17</td>
<td>.91</td>
</tr>
<tr>
<td>Early alliance</td>
<td>−.22</td>
<td>.03</td>
<td>−7.48</td>
<td>p &lt; .001</td>
<td>−.28</td>
<td>−.16</td>
<td>1.00</td>
</tr>
<tr>
<td>Early symptom change</td>
<td>.14</td>
<td>.05</td>
<td>3.01</td>
<td>p = .003</td>
<td>.05</td>
<td>.22</td>
<td>.40</td>
</tr>
</tbody>
</table>

**Table 2**

Mixed Model Parameter Estimates for the Prediction of HAM-D Symptom Reduction Across Treatment Among Patients Receiving CBASP + ADM (n = 224)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>SE</th>
<th>t</th>
<th>Significance</th>
<th>95% CI Lower</th>
<th>95% CI Upper</th>
<th>d</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>14.43</td>
<td>.45</td>
<td>34.16</td>
<td>p &lt; .001</td>
<td>14.93</td>
<td>16.71</td>
<td>4.59</td>
</tr>
<tr>
<td>Female gender</td>
<td>−.06</td>
<td>.62</td>
<td>.11</td>
<td>p = .91</td>
<td>−1.29</td>
<td>1.14</td>
<td>.01</td>
</tr>
<tr>
<td>Age</td>
<td>.01</td>
<td>.03</td>
<td>.45</td>
<td>p = .66</td>
<td>.04</td>
<td>.07</td>
<td>.06</td>
</tr>
<tr>
<td>Baseline GAF</td>
<td>−.25</td>
<td>.04</td>
<td>−6.80</td>
<td>p &lt; .001</td>
<td>−.32</td>
<td>−.17</td>
<td>.91</td>
</tr>
<tr>
<td>Early alliance</td>
<td>−.22</td>
<td>.03</td>
<td>−7.48</td>
<td>p &lt; .001</td>
<td>−.28</td>
<td>−.16</td>
<td>1.00</td>
</tr>
<tr>
<td>Early symptom change</td>
<td>.14</td>
<td>.05</td>
<td>3.01</td>
<td>p = .003</td>
<td>.05</td>
<td>.22</td>
<td>.40</td>
</tr>
</tbody>
</table>

**Table 3a**

Mixed Model Parameter Estimates for the Prediction of HAM-D Symptom Reduction Across Treatment Among Patients Receiving CBASP + ADM (n = 111)

**Note.** Gender reference group = male. HAM-D = Hamilton Rating Scale for Depression; CBASP = cognitive behavioral analysis system of psychotherapy; ADM = antidepressant medication; CI = confidence interval; GAF = Global Assessment of Functioning.

a Intercept reflects estimated mean HAM-D score across all time points.
Early symptom change .29 .05 5.73 /H11002
Early alliance baseline GAF /H11002
Age .06 .03 1.93 /H11002
Female gender /H11002
Intercepta 15.81 .45 34.85 /H11002
Antidepressant medication; BSP /H11002
Hamilton Rating Scale for Depression; WAI /H11002

This hypothesis was not supported. In fact, although we did find a
association would be greater in the BSP than the CBASP group.
We hypothesized that the magnitude of the alliance–outcome
association across different models provides evidence of its critical role across different
approaches to psychotherapy.

We hypothesized that the magnitude of the alliance–outcome
association would be greater in the BSP than the CBASP group.
This hypothesis was not supported. In fact, although we did find a
significant Alliance × Treatment interaction, the association be-
tween the alliance and HAM-D ratings was significantly higher
among patients receiving CBASP compared with BSP. We also
found evidence that participants in the CBASP condition rated
alliance as stronger across treatment than those in BSP.

Because BSP is conceptualized as a “common factors” treat-
ment (Markowitz, Manber, & Rosen, 2008) emphasizing features
that are shared across different models of psychotherapy, including
the therapeutic alliance, we were surprised by both of these find-
ings. In examining WAI subscale scores of early alliance ratings,
we found no differences between BSP and CBASP groups on the
Bond subscale. However, CBASP patients rated the Tasks and
Goals subscale items more highly than those in the BSP condition.
One explanation for these findings is that compared with those in
the nondirective BSP, the structural features of CBASP (e.g.,
situational analysis, a rationale regarding its putative benefits,
between-session homework tasks) enhanced the patients’ sense
that the treatment procedures would be helpful and that their goals
for treatment were aligned with those of their therapists. In gen-
eral, the task and goal dimensions of the therapeutic alliance may
be amplified in a structured treatment emphasizing specific pro-
cedures, compared with a less structured one. Our findings are
consistent with those of Webb et al., 2011, who reported that the
relationship between the WAI (observer-rated) and depression
symptom reduction in CT was significantly related to a factor
comprising patient–therapist agreement on goals and tasks, but not
to a factor assessing affective bond between patient and therapist.

Interestingly, and consistent with others’ findings (Barber et al.,
2001), alliance scores significantly increased in linear fashion over
the 12-week treatment in both groups. We found no evidence of a
V-shaped pattern, reflecting a strong early alliance, followed by
rupture and repair, which has been found in some studies to be
associated with superior outcome (Stiles et al., 2004; Strauss et al.,
2006). However, we only assessed the alliance at three time points,
and we cannot rule out the possibility that more frequent assess-
ment might have revealed such a pattern. Although alliances
improved over the course of treatment, symptom change prior to
assessment of the early alliance did not predict subsequent alliance
ratings, suggesting that alliance ratings were not attributable to
early symptom change. Even so, patients’ experience of the ther-
apeutic alliance may be strengthened by improvement in depres-
sion across later stages of treatment, by increased familiarity and

Table 4
Bivariate Correlations Between Alliance and HAM-D Total Scores

<table>
<thead>
<tr>
<th>Measure</th>
<th>Baseline</th>
<th>Week 2</th>
<th>Week 4</th>
<th>Week 6</th>
<th>Week 8</th>
<th>Week 10</th>
<th>Week 12</th>
</tr>
</thead>
<tbody>
<tr>
<td>WAI total in CBASP + ADM</td>
<td>−.23∗</td>
<td>−.10</td>
<td>−.35**</td>
<td>−.32**</td>
<td>−.23*</td>
<td>−.35**</td>
<td>−.21*</td>
</tr>
<tr>
<td>WAI total in BSP + ADM</td>
<td>−.15</td>
<td>−.16</td>
<td>−.11</td>
<td>−.23*</td>
<td>−.14</td>
<td>−.10</td>
<td>−.13</td>
</tr>
</tbody>
</table>

Note. ns range from 113 to 73 in CBASP + ADM because of missing data. ns range from 113 to 73 in BSP + ADM because of missing data. HAM-D = Hamilton Rating Scale for Depression; WAI = Working Alliance Inventory; CBASP = cognitive behavioral analysis system of psychotherapy; ADM = antidepressant medication; BSP = brief supportive psychotherapy.

∗p < .05. †p < .01.
contact with the therapist, or both. Both the total scores and the change observed over the course of treatment are similar to those reported by Klein et al. (2003) in a previous investigation of the alliance–outcome relationship in chronically depressed patients using the WAI short form.

Little attention has been paid to the relative size of alliance effects in predicting outcome across studies. We found Cohen’s d’s of 1.00 for CBASP + ADM and 0.48 for BSP + ADM. Effect sizes can also be presented as an r statistic. Crits-Christoph and colleagues (2011) recently demonstrated that effects of alliance on treatment outcome are consistently larger when aggregated across multiple observations. These authors found r values of .32, .38, and .41 when predicting outcome in psychotherapy for depression from alliance scores aggregated across Sessions 3–6, 4–7, and 5–8, respectively. While Crits-Cristoph et al. (2011) assessed alliance across multiple treatment modalities, Gaston et al. (1991) isolated independent effects of alliance on outcome in behavior therapy, cognitive therapy, and brief psychodynamic therapy. These authors reported r values between early treatment alliance and outcome of .56, .48, and .42 across the three modalities, respectively. Translating to r values, we found effects of alliance on outcome of .58 and .32 in CBASP and BSP. Thus, our findings are consistent with previously published work.

Given that alliance scores increased as HAM-D scores decreased, we examined whether early symptom change predicted alliance ratings over the course of treatment and did not find a relationship. This finding is consistent with those of Klein et al. (2003), Barber et al. (2000), and Feeley et al. (1999), but not with two other studies (DeRubeis & Feeley, 1990; Strunk et al., 2010). Differences between our findings and those of Strunk et al. (2010) may reflect considerable differences in analytic strategies. We examined the relationship between early change and later alliance, whereas Strunk et al. (2010) focused on only the first five therapist–patient encounters. Among other differences, our sample consisted entirely of chronically depressed patients, and all of our participants received concomitant pharmacotherapy. That early alliance predicted subsequent symptom ratings yet early symptom change did not predict later alliance suggests that the observed increases in alliance across the study are not merely a consequence of patients’ decreased depression. The patient’s perception of their relationship with their therapist does not appear to be attributable to improved mood.

Our study had several limitations that may limit generalizability. First, all patients received psychotherapy in the context of a randomized clinical trial with several unique characteristics. They were initially recruited for an open pharmacotherapy trial from which only partial or nonresponders to medication were randomized to BSP + ADM or CBASP + ADM. Thus, patients may have been somewhat more discouraged compared with those participating in trials that do not select for non- or partial response. In addition, many of these patients may not have been initially seeking psychotherapy, or, conversely, were seeking psychotherapy and had to wait to receive it. Second, both BSP and CBASP were limited to 12 weeks. Third, all patients received concomitant pharmacotherapy; the extent to which these findings apply to settings in which psychotherapy is provided alone is unclear. Klein et al. (2003) found that, among chronically depressed patients receiving CBASP alone or CBASP combined with pharmacotherapy, alliances were stronger in the combined condition, but the relationship between the alliance and outcome was similar in both conditions (Klein et al., 2003). Additionally, the extent of cooperation, collegiality, supervision, and accountability among psychopharmacologists and psychotherapists under clinical trial conditions may differ from community settings. Fourth, some study patients were omitted due to missing data. The current sample comprises approximately 57% of the total number of patients randomized to the two psychotherapy arms of the study (Kocsis et al., 2009). Although we observed no differences between patients whom we included versus those who lacked alliance data, we cannot rule out differences beyond those that were formally assessed. Finally, because there were no significant differences in the primary efficacy measures between the three treatment groups (Kocsis et al., 2009), it could be argued that the significant reductions in depression observed in all three conditions were attributable to the effects of medication. However, we assume that between-group and within-group change are independent. That is, even when mean levels of between-group change are similar, the predictors of change and their magnitude of effects may differ in each group. Conversely, it is possible that levels of change may be significantly different between groups, and yet within-group predictors of change may be similar. Moreover, the working alliance was not assessed in patients receiving medication only, and thus we can neither rule out nor support the possibility that it was a significant predictor of the changes observed in that group.

The above limitations notwithstanding, our study had numerous strengths. These include the randomized design, adequate sample size for testing the study hypotheses, ability to compare the therapeutic alliance–outcome relationship in two psychotherapies with different assumptions regarding the role of the alliance, careful assessment of patients, use of blinded raters, and use of experienced therapists.

To conclude, we found that alliance quality significantly predicted subsequent change in depressive symptoms among patients receiving CBASP and BSP (combined with ADM). The strength of the relationship between the alliance and outcome was significantly greater in CBASP, a more structured psychotherapy compared with BSP. Nonetheless, that early therapeutic alliance significantly predicted subsequent symptom ratings in two dissimilar psychotherapy models after accounting for early improvement in symptoms underscores its consistent and important role in the process of change.

References


Barber, J. P., Khalsa, S. R., & Sharpless, B. A. (2010). The validity of the


Received October 20, 2011
Revision received November 16, 2012
Accepted November 27, 2012

This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.